EATONTOWN, N.J., May 21 /PRNewswire/ -- Roberts Pharmaceutical Corporation
announced today at its Annual Meeting of Shareholders that effective May 22,
1997 the Company's common stock will begin trading on the American Stock
Exchange (AMEX).  Roberts common stock will trade on the AMEX under the symbol
RPC.
    Commenting on today's announcement, Dr. Robert A. Vukovich, President and
CEO of Roberts said "With the recent launch of our first two pipeline
products, Roberts is on the threshold of an exciting new phase in its growth
cycle and our listing on AMEX is consistent with these important corporate
developments and our goal of maximizing shareholder value.  The move from the
dealer oriented OTC market to the public auction market of AMEX is expected to
provide a trading environment for our common stock which will be beneficial to
our shareholders.  Among the benefits expected from a public auction market
are a narrowing in the spread between bid and ask prices; reduced volatility;
enhanced liquidity; and greater visibility. We are pleased to join the growing
family of companies listing with AMEX."
    Roberts Pharmaceutical Corporation, with operating subsidiaries in the
U.S., Canada, and the United Kingdom, focuses on new health care solutions
through the acquisition and development of specialty pharmaceuticals.  The
Company's first proprietary product, ProAmatine(R) was recently launched in
the U.S. as the first drug indicated for treating orthostatic hypotension.
Agrylin(TM), now being launched in the U.S. as first drug indicated for
treating essential thrombocythemia, has been given priority review status in
Canada and should be filed this year for approval in Europe.
    Recent press releases and a letter from the Chairman of the Board of
Roberts Pharmaceutical Corporation are available through PR Newswire's Company
News On-Call fax service at 1-800-758-5804, extension 760975 and on the
internet at http://www.prnewswire.com
     This release may contain forward-looking statements which reflect
management's current views of future events and operations.  These forward-
looking statements are based on assumptions and external factors, including
assumptions relating to regulatory action and competing products.  Any changes
in such assumptions or external factors could produce significantly different
results.

Link to this page: